



PRE *tec* - A REVOLUTION IN SUSTAINABLE AGRICULTURE



PLANT HEALTH CARE PLC

INVESTOR PRESENTATION, 17 DECEMBER 2020



DISCLAIMER

This document comprises a presentation (this "Presentation") which is being supplied to you solely for your information and may not be reproduced, redistributed or passed to any other person or published in whole or in part for any purpose.

This Presentation has been prepared by and is the sole responsibility of Plant Health Care plc (the "Company"). This Presentation does not constitute an offer to sell or a solicitation of offers to buy securities of the Company. This document is not an admission document or a prospectus and persons receiving this Presentation should not subscribe for or purchase shares in the capital of the Company on the basis of the information contained within it.

This Presentation has not been approved by the London Stock Exchange, the US Securities and Exchange Commission or any state securities administrator, or by any authority which could be a competent authority for the purposes of the Prospectus Directive (2003/71/EC). No third party has independently verified any of the information contained in this Presentation.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities in any jurisdiction nor shall it or any part of it form the basis of or be relied on in connection with, or act as any invitation or inducement to enter into, any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on the completeness, accuracy or fairness of such information or opinions. No offer of shares in the capital of the Company is being or will be made in the United Kingdom in circumstances which would require a prospectus approved by the UK Financial Conduct Authority for the purposes of section 87A of the Financial Services and Markets Act 2000.

Nothing in this Presentation constitutes the giving of investment advice. Any person seeking to acquire shares in the Company should conduct their own independent investigation and analysis of the Company and of the information contained in this Presentation. They are advised to seek their own professional advice on the legal, financial and taxation consequences of making any acquisition of shares in the Company.

The information contained in this Presentation is selective and is subject to updating, expansion, completion, revision, amendment and verification.



DISCLAIMER

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its respective Directors, officers, partners, employees, agents, advisers, affiliates, representatives or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and to the fullest extent permitted by law no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this Presentation or its contents otherwise in connection with the subject matter of this Presentation or any transaction.

Furthermore, the Company does not undertake or agree to any obligation to update or correct this Presentation, or to provide any recipient with access to any further information. Notwithstanding the foregoing, nothing in this paragraph shall limit or exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

In the interests of providing information regarding the Company, the Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements appear in a number of places throughout the Presentation and can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "potential", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, financial condition, plans, performance, results of operation, liquidity, prospects, objectives, goals, strategies, future events or intentions. You should not rely upon forward-looking statements except as statements of the Company's present intention and of the Company's present expectations. These forward-looking statements include matters that are not historical facts and speak only as of the date of the Presentation. The Company's expected results may not be achieved and actual results may differ materially from its expectations.

By attending this Presentation and/or accepting a copy of this document, you agree to be bound by the foregoing limitations and, in particular, will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice including without limitation the obligation to use this Presentation and its contents only for the intended purpose set out above.



PRE *TEC* – A REVOLUTION IN SUSTAINABLE AGRICULTURE

WHAT IS PRE *TEC*?

PLANT RESPONSE ELICITOR TECHNOLOGY

- Derived from naturally occurring proteins that stimulate natural defence and growth systems
- Broad pipeline of PREtec peptides, many differentiated products
- Excellent ESG credentials (low toxicity, no residues)¹

“VACCINES FOR PLANTS”

- Deliver increased crop yield and quality
- Resist drought and disease
- Compatible with mainstream agricultural practices
- Low cost of production



WHAT ARE THE BENEFITS TO GROWERS?

EXAMPLE – PHC279: BRAZIL SOYBEANS, 2021 LAUNCH:

- Disease control improved + yield increase worth approx. \$75/Ha²
- ROI potential >6x from yield alone
- Potential value nationwide \$2.5bn
- Use fewer chemicals

WHERE ARE WE TODAY?

- Expect regulatory licences in Brazil (2021) and US (2022)
- Plan first launch in Brazil soybeans in 2021
- Joint Development Agreement with Wilbur-Ellis in US³

CUMULATIVE INVESTMENT >\$20M SINCE 2012: TARGETING MARKETS WORTH \$5BN⁴

1. Exempt from US EPA requirement to establish residue limits.
2. Based on results from Brazil soybean field trials; value based on 38m Ha of soybeans planted in Brazil
3. Wilbur Ellis, a very strong US ag input distributor with \$3.4bn sales, has rights to develop four peptides in specialty crops (fruits and vegetables)
4. Current value of conventional inputs in the markets currently targeted; further markets to be studied



PROGRESS






PRE TEC – SUBSTANTIAL PROGRESS SINCE 2012



THREE PRETEC PLATFORMS DISCOVERED:

- **INNATUS 3G**: disease & yield
- **T-REX 3G**: nematodes
- **Y-MAX 3G**: biostimulant



**GROUND-BREAKING PROPRIETARY PLATFORM IN SUSTAINABLE AGRICULTURE
NOW POISED FOR FIRST LAUNCHES IN VERY LARGE MARKETS**



PHC279 – A WORLD FIRST IN SEED TREATMENT FOR SOYBEANS

BRAZIL SOY: >\$2BN ANNUAL SPEND ON DISEASE CONTROL

TWO YEARS OF STRONG RESULTS:

- Disease control improved + yield increase worth approx. **US\$75/ha¹**
- 38m ha of soy planted in 2020; potential value nationwide \$2.5bn¹

POTENTIAL TO REDUCE USE OF TOXIC FUNGICIDES

- Sustainable disease control
- Strong support from influencers

VERY LARGE GROWER BENEFITS

- ROI potential >6x from yield alone
- Growers want to reduce use of toxic products

SCALING UP PRODUCTION FOR LAUNCH H2 2021

REGISTRATION SUBMITTED 2018

- Expecting approval in H1 2021

MULTIPLE POTENTIAL NATIONAL DISTRIBUTORS TESTING PHC279 IN CURRENT SOY CROP

PHC279 SEED TREATMENT MAKES SOY CROP HEALTHIER

PHC279 TREATED



UNTREATED



PROGRESSING TO LAUNCH PHC279 IN BRAZIL SOYBEANS IN 2021

1. Based on average yield increase. Yield increases as large as 27% compared to the fungicide-only treatment were observed.



PRE *TEC* PRODUCT DEVELOPMENT PROGRESSING IN USA

MULTIPLE PRODUCTS UNDER DEVELOPMENT

EPA SUPPORT AS SUSTAINABLE PRODUCTS

- Low risk; fast-track approval

PHC279: FIELD TRIALS SHOW POTENTIAL IN SOYBEAN, CORN, WHEAT, AS WELL AS FRUITS AND VEGETABLES (SPECIALTY CROPS)

- EPA approval expected H2 2022

PHC949: NEMATODE CONTROL COMPARABLE WITH CHEMICAL STANDARDS

- EPA submission 2021
- Replace toxic soil fumigants (e.g. methyl bromide)

PHC404 SHOWING POTENTIAL IN ALMONDS

- Potential fast-track approval

JDA SIGNED WITH WILBUR-ELLIS® FOR SPECIALTY CROPS

- >\$3.4bn distribution partner, wide market access
- Expect multiple product launches over several years after EPA approval

PRETEC UNDER EVALUATION WITH OTHER PARTNERS FOR ROW CROPS



PRE *TEC* PRODUCTS MOVING FORWARD TO MULTIPLE US LAUNCHES IN MARKETS WORTH >\$3BN



ECONOMICS



THE ECONOMICS OF PRE *TEC* PRODUCTS

SUBSTANTIAL BENEFITS FOR GROWERS

- PHC279 Brazil soybeans: 38 million Ha planted area; \$75/Ha yield increase¹
- PHC414 US strawberries: 45,000 acres²; \$6,000/acre benefit³
- PHC404 US almonds: 1.2 million acres²; \$1,600/acre benefit³

LOW APPLICATION RATES⁴

- Brazil soybeans: single seed treatment, 9 – 27g/Ha⁵
- US strawberries: 8 applications, 60g/acre; total 480g/acre
- US almonds: 4 applications, 57g/acre; total 228g/acre
- Finished product contains 1% peptide

CHEAP TO PRODUCE

- Low cost of production per Kg
 - Confirmed at pilot scale (Penn State)
- Conventional fermentation technology widely available
- Toll manufacturing sources under evaluation; minimal PHC CapEx

SUBSTANTIAL MARGIN OPPORTUNITY

- Price of peptides will vary, depending on value of benefits
- Gross Margin % comparable to Harpin ab (73%)

VERY SUBSTANTIAL MARGIN OPPORTUNITY FOR PHC


1. Based on average yield increase. Yield increases as large as 27% compared to the fungicide-only treatment were observed.
 2. Crop areas from USDA National Agriculture Statistics Service. 3. Benefit based on Plant Health Care small scale field trials and current crop economics.
 4. All application rates stated in grammes of finished product(1% active ingredient). 5. Application rate being refined in current field trials programme



PIPELINE



MULTIPLE PRODUCTS FROM THE PRETEC PIPELINE



PRODUCT PIPELINE TARGETING MARKETS WORTH >\$5BN



MILESTONES



PRE *TEC* MILESTONES 2021-22

PHC279 BRAZIL

- Federal registration H1 2021
- Results from 2020/21 season available mid-2021
- Present at World Soybean Congress, June 2021
- **Launch H2 2021**

PRE *TEC* IN THE USA

- Progress JDA with Wilbur-Ellis®
- Advance discussions with partners for row crops in US
- Achieve PHC279 registration H2 2022
- Submit PHC949 to EPA during 2021
- **Plan multiple launches in 2022/23**

CAPABILITIES

- Appoint toll manufacturer 2021
- Further patent grants to extend IP protection

**LAUNCHING PRETEC PEPTIDES IN VERY LARGE MARKETS WORTH >\$5BN
FIRST LAUNCH H2 2021
A REVOLUTION IN SUSTAINABLE AGRICULTURE**



SUMMARY



SUMMARY

GROUND-BREAKING PROPRIETARY PLATFORM IN SUSTAINABLE AGRICULTURE

PREtec - "VACCINES FOR PLANTS"

SUBSTANTIAL BENEFITS TO GROWERS

- ROI >6x from yield alone
- Promotes sustainable farming

THE PLANT HEALTH CARE OPPORTUNITY

- Broad pipeline of PREtec peptides, many differentiated products
- Excellent ESG credentials (low toxicity, no residues)¹
- High gross margin: comparable to Harpin (73%)
- Scalable global opportunity: Brazil, US, then rolling out globally
- Harvesting sunk investment of >\$20m
- First launch in H2 2021

**LAUNCHING PRETEC PEPTIDES IN VERY LARGE MARKETS WORTH >\$5BN
FIRST LAUNCH H2 2021
A REVOLUTION IN SUSTAINABLE AGRICULTURE**

1. Exempt from US EPA requirement to establish residue limits.